Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SelectQuote (SLQT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- What’s Happe ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violating federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [2][4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of the plans [4]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [4]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [5]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, amid heavy trading volume [5]. - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2].

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced a significant milestone in its partnership with Findhelp, a closed-loop referral management software company at the forefront of powering the U.S. safety net. SelectQuote has directed more than 200,000 low-income seniors, and Findhelp has provided free and reduced-cost social services, addressing cri. ...

Group 1 - SelectQuote, Inc. is facing a federal securities class action, with a deadline of October 10, 2025, for investors to seek the role of lead plaintiff [1] - Investors who purchased or acquired SelectQuote securities are encouraged to contact Kirby McInerney LLP for more information regarding their rights [1] - The announcement highlights the importance of the upcoming deadline for potential plaintiffs in the case [1]

Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the October 10, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by October 10, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices [4] - Specific allegations include directing Medicare beneficiaries to insurers that compensated SelectQuote, not providing unbiased comparisons, receiving illegal kickbacks, and non-compliance with laws and regulations [4] - The lawsuit claims that these actions led to misleading positive statements about SelectQuote's business, resulting in investor damages when the truth was revealed [4]

Core Viewpoint - SelectQuote Inc. is facing significant legal challenges following a whistleblower lawsuit alleging deceptive sales practices, which has resulted in a 19% drop in its share price and a subsequent class-action lawsuit from investors [1][4]. Legal Issues - The U.S. Department of Justice (DOJ) has intervened in a lawsuit against SelectQuote, claiming the company misrepresented its Medicare Advantage sales practices and received improper payments from 2016 to 2021 [3][7]. - The class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., includes investors who purchased stock between September 9, 2020, and May 1, 2025, alleging that SelectQuote misled the market regarding its business model and regulatory risks [2][5]. Market Reaction - Following the DOJ's involvement, SelectQuote's stock experienced a nearly 20% decline in a single day, and shares have fallen over 40% in the past six months due to investor concerns about legal exposure and reputational damage [4][5]. Allegations of Misconduct - The lawsuit claims that SelectQuote directed customers towards higher-commission plans, accepted illegal kickbacks, and violated federal statutes, including the False Claims Act [6][7]. - Hagens Berman is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, suggesting that the company's claims of providing "unbiased advice" may have been misleading [6].

Core Viewpoint - SelectQuote, Inc. is facing a securities fraud class action lawsuit, and investors who have suffered losses are encouraged to contact legal representation to discuss their rights [1] Group 1 - Investors have until October 10, 2025, to request the Court to appoint them as lead plaintiff in the lawsuit [1]

Core Viewpoint - SelectQuote, Inc. is facing a securities fraud class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misrepresentations about its business practices [4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025 [4]. - The allegations include that the Company and certain senior officers made misrepresentations regarding the legality of its business practices [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff must file papers by October 10, 2025, with the role involving acting on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and shareholders incur no fees or expenses as representation is on a contingency fee basis [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [6]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote rather than providing unbiased comparisons [4]. - It is claimed that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers, which resulted in non-compliance with applicable laws and regulations [4]. - The lawsuit asserts that the misleading statements about SelectQuote's business operations led to investor damages when the true details became public [4].